Bank of America upgraded shares of Laboratory Corp. of America (NYSE:LH) from an underperform rating to a neutral rating in a report published on Tuesday, Benzinga reports. The firm currently has $174.60 price target on the medical research company’s stock.

Several other analysts also recently issued reports on the company. Wolfe Research started coverage on Iqvia in a research note on Tuesday, April 2nd. They set a market perform rating for the company. Mizuho set a $31.00 target price on Evolus and gave the company a buy rating in a research note on Monday, May 20th. Citigroup increased their target price on Martin Marietta Materials from $239.00 to $255.00 and gave the company a buy rating in a research note on Wednesday, May 1st. Jefferies Financial Group restated a sell rating on shares of Hi-Crush Partners in a research note on Tuesday, April 2nd. Finally, Deutsche Bank restated a buy rating and set a GBX 2,450 ($32.01) target price on shares of in a research note on Thursday, June 20th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Laboratory Corp. of America currently has a consensus rating of Buy and an average price target of $182.60.

Shares of LH traded down $0.10 during trading hours on Tuesday, hitting $174.87. 81,231 shares of the company were exchanged, compared to its average volume of 613,796. The company has a market capitalization of $17.23 billion, a P/E ratio of 15.87, a PEG ratio of 1.59 and a beta of 1.04. The company’s 50 day simple moving average is $170.32. Laboratory Corp. of America has a 52 week low of $119.38 and a 52 week high of $188.65. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.05 and a current ratio of 1.14.

Laboratory Corp. of America (NYSE:LH) last released its quarterly earnings results on Tuesday, April 30th. The medical research company reported $2.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.09. The company had revenue of $2.79 billion during the quarter, compared to the consensus estimate of $2.82 billion. Laboratory Corp. of America had a return on equity of 16.59% and a net margin of 8.59%. The firm’s revenue was down 2.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.78 EPS. On average, equities analysts expect that Laboratory Corp. of America will post 11.28 earnings per share for the current year.

In other Laboratory Corp. of America news, CFO Glenn A. Eisenberg sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $167.40, for a total value of $1,674,000.00. Following the completion of the transaction, the chief financial officer now owns 28,366 shares of the company’s stock, valued at approximately $4,748,468.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Lisa J. Uthgenannt sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $164.00, for a total value of $656,000.00. Following the completion of the transaction, the insider now directly owns 4,638 shares of the company’s stock, valued at approximately $760,632. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,191 shares of company stock valued at $4,948,144. 0.74% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the business. Shine Investment Advisory Services Inc. raised its holdings in Laboratory Corp. of America by 30.7% in the 1st quarter. Shine Investment Advisory Services Inc. now owns 277 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 65 shares in the last quarter. ETF Managers Group LLC raised its holdings in shares of Laboratory Corp. of America by 8.1% in the 1st quarter. ETF Managers Group LLC now owns 883 shares of the medical research company’s stock worth $135,000 after buying an additional 66 shares in the last quarter. Diversified Trust Co raised its holdings in shares of Laboratory Corp. of America by 4.1% in the 2nd quarter. Diversified Trust Co now owns 1,763 shares of the medical research company’s stock worth $305,000 after buying an additional 70 shares in the last quarter. Private Trust Co. NA raised its holdings in shares of Laboratory Corp. of America by 1.4% in the 2nd quarter. Private Trust Co. NA now owns 5,172 shares of the medical research company’s stock worth $894,000 after buying an additional 72 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. raised its holdings in shares of Laboratory Corp. of America by 1.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 7,827 shares of the medical research company’s stock worth $1,197,000 after buying an additional 74 shares in the last quarter. 91.49% of the stock is owned by hedge funds and other institutional investors.

About Laboratory Corp. of America

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Further Reading: How are dividend achievers different from dividend aristocrats?

Analyst Recommendations for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.